関: Recombinant human erythropoietin

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 組換え造血成長因子の概要introduction to recombinant hematopoietic growth factors [show details]
…contribute to wound healing responses, angiogenesis, and the response to brain and heart injury . Recombinant human EPO has had a major impact on the quality of life in patients with marked anemia due to chronic …
2. 人工透析を受けていない慢性腎臓病患者に生じる貧血の治療treatment of anemia in nondialysis chronic kidney disease [show details]
…associated with increased mortality and cardiovascular events independent of Hb level . Methoxy polyethylene glycol-epoetin beta has also been approved for use in patients who have nondialysis CKD, with a recommended …
3. 癌患者での貧血における赤血球生成刺激剤の役割role of erythropoiesis stimulating agents in the treatment of anemia in patients with cancer [show details]
…requirements) . Epoetin alfa is indicated for the treatment of chemotherapy-induced anemia in nonmyeloid malignancies. Epoetin alfa can be administered weekly or three times weekly When epoetin alfa was initially …
4. 抗エリスロポエチン刺激因子抗体による赤芽球癆（PRCA）pure red cell aplasia prca due to anti erythropoiesis stimulating agent antibodies [show details]
…exogenous ESAs crossreact with endogenous EPO. There are several preparations of epoetins (ie, epoetin alfa, epoetin beta, epoetin omega, and others) produced by various manufacturers around the world. They differ …
5. 腎移植レシピエントの貧血anemia and the kidney transplant recipient [show details]
…clinical outcomes . In a randomized trial of 104 patients that examined the efficacy of high-dose epoetin beta before transplant and during the first two weeks posttransplant, there was no difference in the …

English Journal

EPO could be regulated by HIF-1 and promote osteogenesis and accelerate bone repair.

Yu Y, Ma L, Zhang H, Sun W, Zheng L, Liu C, Miao L.
Artificial cells, nanomedicine, and biotechnology. 2020 Dec;48(1)206-217.
Bone defects caused by many factors prompt further study of pathological process and restoration methods. This study was aimed to clarify the effect of erythropoietin on the repair of bone defect. We added the designated concentration of rhEPO to endothelial progenitor cells and marrow stromal cells
PMID 31851837

Analysis of glycopeptide biomarkers by on-line TiO solid-phase extraction capillary electrophoresis-mass spectrometry.

Mancera-Arteu M, Lleshi N, Sanz-Nebot V, Giménez E, Benavente F.
Talanta. 2020 Mar;209()120563.
In this study is described an on-line titanium dioxide solid-phase extraction capillary electrophoresis-mass spectrometry (TiO-SPE-CE-MS) method for the analysis of the glycopeptide glycoforms obtained from the tryptic digests of recombinant human erythropoietin (rhEPO). The O-glycopeptide of rhEPO
PMID 31892091

Elevation of stromal cell-derived factor 1 and C-X-C chemokine receptor type 4 in white matter damage treatment with recombinant human erythropoietin and human umbilical cord mesenchymal stem cells in a rat model of preterm birth.

Yin L, Wang S, Zhang N, Bai X, Xie J, Wen Q, Huang L, Qian L, Jiang L.
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. 2020 Feb;().
To investigate the role of stromal cell-derived factor 1 (SDF-1) and C-X-C chemokine receptor type 4 (CXCR-4) in the premature brain with white matter damage (WMD) undergoing treatment with human umbilical cord mesenchymal stem cells (hUC-MSCs) and recombinant human erythropoietin (rhEPO). Three-day
PMID 32108377